Investigational drug · Phase 3
rHuPH20
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
149
Any phase or sponsor naming "rHuPH20"
First trial start
2021
May 21, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "rHuPH20", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
- Relapsing-remitting Multiple Sclerosis
- Clear Cell Renal Cell Carcinoma
- HIV Infections
Approved drugs for the same conditions: Melanoma · Kidney cancer (renal cell carcinoma) · Multiple sclerosis · Oncology · Neurology · Infectious disease and vaccines · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "rHuPH20" as an intervention, largest first.
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialPivotal-lookingRecruiting
ECOG-ACRIN Cancer Research GroupResearch network
NCT04566328 · 1,450 participants (planned) · Start Feb 24, 2021 · Primary completion Dec 31, 2027
Drug: Bortezomib; Daratumumab and Hyaluronidase-fihj and 2 more · For: Plasma Cell Myeloma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 647 sites in all
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT04071457 · 1,100 participants (planned) · Start Aug 13, 2019 · Primary completion Sep 2032
Drug: Lenalidomide; Daratumumab/rHuPH20 · For: Multiple Myeloma
Sites: Anchorage, Alaska; Fairbanks, Alaska; Kingman, Arizona · 842 sites in all
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05296798 · 922 participants (planned) · Start Jul 18, 2022 · Primary completion Jun 15, 2028
Drug: Phesgo; Giredestrant and 4 more · For: Locally Advanced or Metastatic Breast Cancer
Sites: Tucson, Arizona; Los Angeles, California; Jacksonville, Florida · 198 sites in all
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaPivotal-lookingNot yet recruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT07887984 · 920 participants (planned) · Start Dec 23, 2026 · Primary completion Aug 1, 2033
Drug: Daratumumab and Recombinant Human Hyaluronidase; Lenalidomide and 5 more · For: Multiple Myeloma (MM)
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT07383441 · 718 participants (planned) · Start Jun 5, 2026 · Primary completion Jan 31, 2033
Drug: Axitinib; Cabozantinib and 7 more · For: Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8 and 1 more
Sites: Fayetteville, Arkansas; Jonesboro, Arkansas; Rogers, Arkansas · 41 sites in all
- A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT04810078 · 681 participants · Start May 21, 2021 · Primary completion Jul 29, 2025
Drug: Nivolumab and rHuPH20; Nivolumab · For: Clear Cell Renal Cell Carcinoma
Sites: Chicago, Illinois; Buffalo, New York; West Reading, Pennsylvania · 89 sites in all
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaPivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05625399 · 579 participants · Start Mar 6, 2023 · Primary completion Aug 4, 2025
Drug: Nivolumab + Relatlimab; rHuPH20 · For: Melanoma
Sites: Phoenix, Arizona; Springdale, Arkansas; Los Angeles, California · 149 sites in all
- A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03277105 · 522 participants · Start Oct 27, 2017 · Primary completion Jun 27, 2019
Drug: Dara SC; Dara IV · For: Multiple Myeloma
Sites: Boston, Massachusetts; Charlotte, North Carolina; Camperdown, Australia · 146 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05498428 · 520 participants (planned) · Start Nov 11, 2022 · Primary completion Aug 17, 2027
Drug: Amivantamab; Lazertinib and 4 more · For: Carcinoma, Non-small-Cell Lung
Sites: La Jolla, California; Orange, California; Stanford, California · 110 sites in all
- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT05561387 · 510 participants (planned) · Start Oct 12, 2023 · Primary completion May 30, 2031
Drug: Bortezomib; Daratumumab and Hyaluronidase-fihj and 2 more · For: Plasma Cell Myeloma
Sites: Anchorage, Alaska; Phoenix, Arizona; Fort Smith, Arkansas · 397 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Process development for high-purity recombinant hyaluronate lyase preparation, its specific HA degradation profile and chemosensitizing potential in lung cancer combined chemotherapy.
Shi Y, Si B, Li Q, et al. · J Biotechnol 2026
- rHuPH20 Enhances Extravascular Delivery of mRNA Lipid Nanoparticles in Mice and Minipigs.
Nolan RP, Printz MA, Kang DW, et al. · Nucleic Acid Ther 2026
- Hyaluronidase-enhanced delivery in gene therapy and regenerative medicine for improved vector, cell, and cargo access.
Sewell PE, Jensen C · Front Drug Deliv 2026
- Transitioning Therapeutic Antibodies in Oncology from Intravenous to Hyaluronidase-Facilitated Subcutaneous Administration.
Xu XS · Clin Pharmacokinet 2026
- Optimizing Subcutaneous Antibody Dosing Regimens Through Operating Space Maps: rHuPH20 Case Study.
Nolan RP, Chintakuntla H · J Pharmacokinet Pharmacodyn 2026
- Translating a Preclinical Hydrogel Platform into a Human Therapeutic for Delivering Targeted Low-Dose Anti-CTLA-4.
Harui A, Roth MD · Gels 2026
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.